Global healthcare company Novo Nordisk is planning to acquire obesity drug maker Inversago Pharma for up to $1.08 billion, the company announced Thursday.
However, the final acquisition price will hinge on Inversago’s reaching specific sales and development milestones.
Inversago develops therapies for treating diabetes, obesity and other metabolic conditions using protein blockers.
The acquisition announcement comes as Novo Nordisk’s looks to continue capitalizing on the ongoing weight loss drug craze.
